Krystal Biotech shares are trading higher as the market revisits the company’s near-term catalyst slate and signs of sustained VYJUVEK demand. The company’s latest operating commentary emphasized broad U.S. reimbursement coverage and continued uptake internationally, which is supporting sentiment around durability of the current revenue base and the potential for incremental growth from additional launches. (ir.krystalbio.com)

In its fourth-quarter/full-year 2025 update, Krystal said it had secured over 660 reimbursement approvals for VYJUVEK in the U.S. and estimated more than 90 patients prescribed therapy across Germany, France, and Japan, underscoring continued penetration beyond the initial U.S. launch. The same update also outlined ongoing pricing/reimbursement discussions in Europe and pointed to a potential Italy launch in the second half of 2026, extending the narrative of international commercialization as an additional leg of growth. (ir.krystalbio.com)

Beyond the marketed product story, investors are also positioning around a dense 2026 clinical calendar. Krystal has communicated expectations to complete enrollment in its Phase 3 registrational IOLITE study of KB803 in the first half of 2026 with top-line results before year-end, and to align with the FDA and start enrollment in the CORAL-3 repeat-dosing study for KB407 in the first half of 2026—two events that could broaden the platform’s value proposition if execution stays on track. (ir.krystalbio.com)

Near-term attention is likely to center on (1) evidence that VYJUVEK prescribing continues to expand while European pricing negotiations proceed, and (2) confirmation of timelines for KB803 and KB407 milestones. Any additional regulatory designations or interim clinical readouts could amplify volatility given the stock’s sensitivity to pipeline headlines and the market’s focus on whether Krystal can translate platform breadth into multiple marketed medicines over time. (ir.krystalbio.com)